This article is the third installment in the “Ask Dr. Kevin” series, brought to you by Pﬁzer Rare Disease in collaboration with the National Newspaper Publishers Association (NNPA) to increase understanding of sickle cell disease.
Clinical trials are critical to bringing new medicines to people who need them, particularly those affected by conditions with limited treatment options, such as sickle cell disease (SCD). These studies, which determine the safety and effectiveness of new investigational treatments, rely on the participation of volunteers.
Without enough volunteers, researchers are unable to complete the research required by the U.S. Food and Drug Administration (FDA) to evaluate if a new drug should be made available to patients. Therefore, the only way to get any drug approved by the FDA and accessible to patients in need is through clinical trials.
Unfortunately, finding enough patient volunteers is often a challenge in conducting clinical trials, and this has been particularly true for trials exploring new treatment options for SCD, which occurs in one out of every 365 African American births. Although African Americans make up 12 percent of the U.S. population, they comprise only 5 percent of clinical trial participants overall.
Fear and misunderstanding about clinical trials likely contribute to the difficulty of recruiting participants. Recently, Pﬁzer and the NNPA collaborated on a national poll consisting of 741 participants to learn more about perceptions of SCD and clinical trials in the African American community. A majority of respondents indicated a willingness to participate in future clinical trials for SCD, if given appropriate knowledge and recommendations from health care professionals. Of those who indicated that they would not participate in clinical trials, ‘fear of uncertainties’ was the most cited reason.
To help address some of these uncertainties, I’m here to answer the most common questions about clinical trials. It is my hope that this information will help you make an informed decision should you or a loved one choose to participate in a clinical trial in the future.
Are clinical trials safe?Strict guidelines and supervision are in place to protect the safety of people who take part in studies—from careful study design to periodic monitoring of study data by independent experts. That said, clinical trials are designed for research purposes, and because of this, there is some level of risk involved. However, before an investigational drug can be given to clinical trial volunteers, researchers must complete a rigorous screening and preclinical testing process (in the laboratory and in animals), which can take up to six years to complete.
If I participate in a clinical trial, will I get a “sugar pill” or placebo instead of a real drug?
Participants in a clinical trial using a placebo will always be informed if there is a possibility they could be receiving the placebo, which looks identical to the real drug but does not contain the active ingredient.
However, the vast majority of studies are not placebo-controlled trials, and patients in the clinical trial who are not receiving the drug under study will receive the current standard of care available to the public.
Patients who take part in clinical trials will never be asked to sacriﬁce quality of care.
Will it be expensive to participate in a clinical trial?
Patient care costs are generally covered by health insurance, as they are for tests and treatments you would receive even if you were not involved in the research. The majority of participants in clinical studies receive at least some reimbursement from their health insurance. Most often, the clinical trial sponsors will pay for the study therapy and insurance companies will pay for the routine care procedures, such as blood tests.
Before participating in clinical trials, I recommend checking with the researchers regarding your financial responsibilities as a patient, as well as with your health insurance carrier regarding coverage.
How do I ﬁnd out about clinical trials?
You can always talk to your doctor; however, he or she may not know about all available clinical trials that might apply to you. Only approximately 1 in 5 patients say that their health care professionals have talked to them about participating in a clinical trial.
As for resources, the National Institutes of Health has an online database that is a great tool to search for appropriate trials: https://clinicaltrials. gov. Another great resource is “I’m In,” a campaign to build awareness about the importance of diversity in clinical trials, especially among African Americans, Asian Americans, and Hispanic populations. You can ﬁnd more information on Pﬁzer’s Clinical Trial page, too.
What’s the time-frame for clinical trials?
I’m often asked, “Why does a new treatment take so long?” The short answer is that treatment takes as long as it does because the cardinal rule of medicine is “First, do no harm.” Thus, the development of a new therapy is a multi-stage, complex process that has to meet the highest standards of patient protection.
Clinical trials, which generally take 5 to 10 years, are at the center of the rigorous science that demonstrates the safety and efficacy of a medicine and provides a thorough view of its beneﬁts and risks, and is the only avenue to bring medications to patients in need.
The next Ask Dr. Kevin article will appear next year. Meanwhile, here are resources to find more information about sickle cell disease, the collaboration between the NNPA and Pﬁzer Rare Disease, and a new nationwide poll conducted by Howard University to deepen understanding and gauge perceptions around SCD and clinical trials among African Americans.
[Dr. Kevin Williams is the Chief Medical Ofﬁcer for Rare Disease at Pﬁzer. He pursued medicine after being inspired by his father’s work as a general practitioner in his hometown of Baton Rouge, Louisiana. Dr. Kevin is passionate about raising awareness and increasing understanding of sickle cell disease in the African American community. You can follow Pﬁzer on Facebook and Twitter.]